Norman Ng, Director of Patient Advocacy and Public Affairs at Healthcare Thinkers, shared on LinkedIn:
“Mainland original RandD + Hong Kong international business channels, complementing each other’s strengths and achieving a win-win situation:
- We hope that rigorously clinically validated original Chinese oncology therapies will be available in Hong Kong and Macau as soon as possible, bringing more precise treatment options to local patients with advanced tumors;
- Attempt to use Hong Kong and Macau as pilot bridgeheads, accumulating cross-border registration, real-world data, and market operation experience, paving the way for more domestic innovative drugs to expand into Southeast Asia and go global;
- Explore an industry collaboration model of “Mainland R&D, Hong Kong Commercialization, and Global Expansion,” leveraging Hong Kong’s strategic role as the country’s international gateway for biotechnology.
Through three parallel approaches: ‘establishing a local self-built business team deeply rooted in the mainland, partnering with new fronts to expand into Hong Kong and Macau, and licensing multinational pharmaceutical companies to develop overseas.’ it has built a complete global layout; New Frontier, leveraging its local medical network advantages, efficiently delivers high-value innovative therapies to patients. The ultimate significance of scientific breakthroughs remains to narrow the gap in medical resources, enabling patients in need to access high-quality new drugs.
We look forward to both parties steadily advancing various preparatory work after the formal agreement is finalized, so that cancer patients in Hong Kong and Macau can access this innovative domestic ADC drug as soon as possible.
Other articles about Norman Ng on OncoDaily.
